Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis

Clinical trials for Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis explained in plain language.

Never miss a new study

Get alerted when new Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis trials appear

Sign up with your email to follow new studies for Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New pill aims to tame rare blood vessel disease

Disease control Ongoing

This phase 2 trial tests whether adding the oral drug iptacopan to standard therapy (rituximab) helps people with active ANCA vasculitis achieve and maintain remission. About 84 adults with newly diagnosed or relapsed disease will receive either iptacopan or a placebo, plus stand…

Matched conditions: ANTI-NEUTROPHIL CYTOPLASM ANTIBODIES (ANCA) ASSOCIATED VASCULITIS

Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Aug 22, 2026 00:00 UTC

Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis

Get alerted when new Anti-neutrophil cytoplasm antibodies (ANCA) associated vasculitis trials appear

New pill aims to tame rare blood vessel disease